VIDEO: Advantages of aggressive therapy for metastatic EGFR-mutated NSCLC
In this video, Julia K. Rotow, MD, medical oncologist at Dana-Farber Cancer Institute, discussed high-dose hypofractionated radiotherapy in combination with tyrosine kinase inhibitors for the treatment of EGFR-mutated non-small cell lung cancer with limited metastatic disease.
“While they saw improvements in PFS, they also showed improvements in OS, which were fairly significant,” she said. “It does maybe add some additional support for our use of more aggressive RT therapy as our RT strategies have improved.”
Rotow also mentioned the recent FDA approval of selpercatinib for the treatment of RET fusion-positive NSCLC. She highlighted findings from a subgroup analysis of data from the LIBRETTO-001 trial that focused on the activity of selpercatinib against central nervous system metastases.
Reference:
- Santarpia M, et al. Abstract e21580. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
- Subbiah V, et al. Abstract 9516. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Collapse